Quote:

---

They can push the thumbs down but can't tell me where I am off the mark.

---

Okay...

Quote:

---

Discussions with Big Pharma...give me a break. I heard this every call since I bought in Q1 of 2018, and it's a joke.

---

In 2018, we had no EIND, no COVID data. In the midst of a pandemic, if LL data proves efficacy, of course Big Pharma will be kicking the tires. We also didn't have any cancer data and were not aware of BBB success back then.

Quote:

---

NASDAQ DOA.

---

Maybe, but not necessarily. If CD12 *does* get EUA in 2 weeks, the pps will be a lot higher and no reason uplisting couldn't be completed.

Quote:

---

Longhaulers is a waste of time.

---

Disagree. COVID isn't going anywhere. The very name "Longhaulers" describes people with serious ailments that aren't going away, maybe ever without treatment. They need therapy. LL could be huge in that market.

Quote:

---

Full enrollment on CD12 is 4-6 months from having data we could use.

---

I'd say 3-4 months. If the DSMB says continue the trial, that means it likely looks good and enrollment may speed up. NP indicates more trial sites coming online already. Lots of naysayers were griping about speed of CD10 and that filled up at the end very quickly.